118737-62-5

Basic information

• Product Name: 2,4-DIFLUOROBENZOIC ACID HYDRAZIDE
• Synonyms: BUTTPARK 35\03-74;2,4-DIFLUOROBENZOIC ACID HYDRAZIDE;2,4-DIFLUOROBENZHYDRAZIDE;2,4-DIFLUOROBENZOHYDRAZIDE;2,4-DIFLUOROBENZOIC HYDRAZIDE;2,4-Difluorobenzoic acid hydrazide 97%;2,4-Difluorobenzoicacidhydrazide97%;2,4-difluorobenzene-1-carbohydrazide
• CAS NO: 118737-62-5
• Molecular Formula: C7H6F2N2O
• Molecular Weight: 172.13
• Product Categories: Fluorine Compounds
• Mol File: 118737-62-5.mol
• Article Data: 6

Chemical Properties

• Melting Point: 141 °C
• Appearance: /
• Density: 1.373 g/cm³
• Refractive Index: 1.53
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 11.44±0.10(Predicted)
• CAS DataBase Reference: 2,4-DIFLUOROBENZOIC ACID HYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DIFLUOROBENZOIC ACID HYDRAZIDE(118737-62-5)
• EPA Substance Registry System: 2,4-DIFLUOROBENZOIC ACID HYDRAZIDE(118737-62-5)

Safety Data

• Hazard Codes: Xi
• Statements: 20/21/22
• Safety Statements: 22-36/37/39
• Hazardous Substances Data: 118737-62-5(Hazardous Substances Data)

Usage

General Description

2,4-DIFLUOROBENZOIC ACID HYDRAZIDE is a chemical compound with the molecular formula C7H6F2N2O2. It is a hydrazide derivative of 2,4-difluorobenzoic acid and is used in the synthesis of pharmaceuticals and agrochemicals. It is a white to off-white crystalline solid with a molecular weight of 184.13 g/mol. 2,4-DIFLUOROBENZOIC ACID HYDRAZIDE is known for its potential use as a building block in organic synthesis and as a reagent in chemical reactions. It is important to handle this compound with care as it may pose hazards to human health and the environment.

InChI:InChI=1/C7H6F2N2O/c8-4-1-2-5(6(9)3-4)7(12)11-10/h1-3H,10H2,(H,11,12)

Upstream product

• 72482-64-5 2,4-difluorobenzoyl chloride 
• 108928-00-3 ethyl 2,4-di-fluorobenzoate 
• 1583-58-0 2,4-difluoro-benzoic acid 
• 106614-28-2 methyl 2,4-difluorobenzoate 

Downstream Products

• 1356585-72-2 C₁₀H₈F₂N₂O₃S 
• 1257543-46-6 C₁₄H₁₀ClF₂N₃OS 
• 1254071-39-0 7-{[2-chloro-3-(trifluoromethyl)phenyl]carbonyl}-3-(2,4-difluorophenyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine 
• 329974-19-8 2,4-difluorobenzoic acid (1-amino-2-benzenesulfonylethylidene)hydrazide 

Relevant articles and documents

Design, synthesis, and evaluation of N-benzylpyrrolidine and 1,3,4-oxadiazole as multitargeted hybrids for the treatment of Alzheimer's disease

Novel N-Benzylpyrrolidine hybrids were designed, synthesized, and tested against multiple in-vitro and in-vivo parameters. Among all the synthesized molecules, 8f and 12f showed extensive inhibition against beta-secretase-1 (hBACE-1), human acetylcholinesterase (hAChE) & human butyrylcholinesterase (hBuChE). These molecules are also endowed with significant AChE-peripheral anionic site (PAS) binding capability, blood-brain barrier permeability, potential disassembly of Aβ aggregates along with neuroprotection ability on SHSY-5Y cell lines. Results of the Y-Maze and Morris water maze test concluded that compounds 8f and 12f ameliorated cognitive dysfunction induced by scopolamine and Aβ. The ex-vivo activity was executed on rat's brain homogenate indicating a reduction in AChE level and oxidative stress. The pharmacokinetic investigation ascertained considerable oral absorption profile of the lead 12f. The results of the in silico docking studies and molecular dynamics simulations demonstrated stable interactions of compounds 8f and 12f with the target residues of hAChE, hBuChE and hBACE-1.

Novel Molecular Hybrids of N-Benzylpiperidine and 1,3,4-Oxadiazole as Multitargeted Therapeutics to Treat Alzheimer's Disease

Multitargeted hybrids of N-benzylpiperidine and substituted 5-phenyl-1,3,4-oxadiazoles were designed, synthesized, and evaluated against Alzheimer's disease (AD). Tested compounds exhibited moderate to excellent inhibition against human acetylcholinesterase (hAChE), butyrylcholinesterase (hBChE), and beta-secretase-1 (hBACE-1). The potential leads 6g and 10f exhibited balanced inhibitory profiles against all the targets, with a substantial displacement of propidium iodide from the peripheral anionic site of hAChE. Hybrids 6g and 10f also elicited favorable permeation across the blood-brain barrier and were devoid of neurotoxic liability toward SH-SY5Y neuroblastoma cells. Both leads remarkably disassembled Aβ aggregation in thioflavin T-based self- and AChE-induced experiments. Compounds 6g and 10f ameliorated scopolamine-induced cognitive dysfunctions in the Y-maze test. The ex vivo studies of rat brain homogenates established the reduced AChE levels and antioxidant activity of both compounds. Compound 6g also elicited noteworthy improvement in Aβ-induced cognitive dysfunctions in the Morris water maze test with downregulation in the expression of Aβ and BACE-1 proteins corroborated by Western blot and immunohistochemical analysis. The pharmacokinetic study showed excellent oral absorption characteristics of compound 6g. The in silico molecular docking and dynamics simulation studies of lead compounds affirmed their consensual binding interactions with PAS-AChE and aspartate dyad of BACE-1.

SELECTIVE HDAC6 INHIBITORS

The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (HDAC6) enzyme.